Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

被引：0
|
作者：
Mathilde Bureau
Thierry Chatellier
Tanguy Perennec
Thomas Goronflot
Charlotte Greilsamer
Anne-Laure Chene
Raafet Affi
Eric Frampas
Jaafar Bennouna
Elvire Pons-Tostivint
机构：
[1] University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de Nantes
[2] Medical Oncology Unit,Department of Radiation Oncology
[3] Institut de Cancerologie de L’Ouest,INSERM
[4] University Hospital of Nantes,Pneumology Unit
[5] Medical Oncology Unit,Radiology Unit
[6] University Hospital of Nantes,undefined
[7] University Hospital of Nantes,undefined
[8] INSERM,undefined
[9] CRCINA,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Baseline tumour size; Non-small cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1747 / 1756
页数：9
相关论文
共 50 条
  • [41] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [42] Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy
    Mingjia Li
    Songzhu Zhao
    Gabrielle Lopez
    Austin Secor
    Parthib Das
    Nitya Surya
    Madison Grogan
    Sandip Patel
    Karthik Chakravarthy
    Abdul Miah
    Daniel Spakowicz
    Gabriel Tinoco
    Zihai Li
    Lai Wei
    Kai He
    Erin Bertino
    Asrar Alahmadi
    Regan Memmott
    Jacob Kaufman
    Peter G. Shields
    David P. Carbone
    Carolyn J. Presley
    Gregory A. Otterson
    Dwight H. Owen
    Cancer Immunology, Immunotherapy, 2023, 72 : 2067 - 2074
  • [43] Investigation on the survival implications of PD-L1 expression status in ALK-rearranged advanced non-small cell lung cancer treated with first-line crizotinib
    Zhou, Yuling
    Song, Lianxi
    Xu, Qinqin
    Zeng, Liang
    Jiang, Wenjuan
    Yang, Nong
    Zhang, Yongchang
    LUNG CANCER, 2022, 167 : 58 - 64
  • [44] Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC)
    Li, Mingjia
    Zhao, Songzhu
    Chian, Kenneth
    Kwon, Hyunwoo
    Jones, Nicholas
    Khorasanchi, Adam
    Gauntner, Timothy
    Coss, Christopher C.
    Phelps, Mitch A.
    Spakowicz, Daniel
    Wei, Lai
    Alahmadi, Asrar
    Memmott, Regan Michelle
    Kaufman, Jacob
    He, Kai
    Shields, Peter G.
    Carbone, David Paul
    Otterson, Gregory Alan
    Presley, Carolyn J.
    Owen, Dwight Hall
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] FIRST-LINE PEMBROLIZUMAB IN PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS FROM A UK HEALTHCARE PERSPECTIVE
    Hu, X.
    Goldman, D. P.
    VALUE IN HEALTH, 2017, 20 (09) : A399 - A399
  • [46] A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer.
    Goldstein, Daniel A.
    Gordon, Noa
    Davidescu, Michal
    Leshno, Moshe
    Steuer, Conor Ernst
    Patel, Nikita
    Stemmer, Salomon M.
    Zer, Alona
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    Popat, Sanjay
    Liu, Stephen V.
    Scheuer, Nicolas
    Gupta, Alind
    Hsu, Grace G.
    Ramagopalan, Sreeram V.
    Griesinger, Frank
    Subbiah, Vivek
    JAMA NETWORK OPEN, 2022, 5 (05) : E2214046
  • [48] Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?
    Bozkaya, Yakup
    Kostek, Osman
    Sakin, Abdullah
    Ozyukseler, Deniz Tataroglu
    Sakalar, Teoman
    Cil, Ibrahim
    SUPPORTIVE CARE IN CANCER, 2020, 28 (05) : 2273 - 2282
  • [49] Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
    Pons-Tostivint, E.
    Hulo, P.
    Guardiolle, V.
    Bodot, L.
    Rabeau, A.
    Porte, M.
    Hiret, S.
    Demontrond, P.
    Curcio, H.
    Boudoussier, A.
    Veillon, R.
    Mayenga, M.
    Dumenil, C.
    Chatellier, T.
    Gourraud, P. A.
    Mazieres, J.
    Bennouna, J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (06) : 1881 - 1890
  • [50] Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?
    Yakup Bozkaya
    Osman Köstek
    Abdullah Sakin
    Deniz Tataroğlu Özyükseler
    Teoman Şakalar
    İbrahim Çil
    Supportive Care in Cancer, 2020, 28 : 2273 - 2282
12345